Literature DB >> 22207871

Don't live in a town where there are no doctors: toxic epidermal necrolysis initially misdiagnosed as oral thrush.

Abdul Majid Wani1, Waleed Mohd Hussain, Mohamad Ibrahim Fatani, Khaled Shawkat Ali, Amer Mohd Khoujah, Mubeena Akhtar, Ghassan Adnan Al Maimani, Sadeya Hanif Raja, Ashraf Basraheel, Khurram Fareed.   

Abstract

Toxic epidermal necrolysis (TEN) is a rare but life threatening skin disease that is most commonly drug induced. The exact pathogenesis of TEN is still unknown and many drugs, including prednisolone, cyclosporin and intravenous immunoglobulin (IVIG), have been used in an attempt to halt the disease process. The use of IVIG in particular is controversial. Recently, the US Food and Drug Administration (FDA) has made a labelling change to the drug information for carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine induced Stevens-Johnson syndrome and TEN in Han Chinese, the FDA recommends genotyping all Asians for the allele. We present an interesting case of carbamazepine induced TEN which was confused with oral thrush, had no skin lesions on presentation, and had an excellent response to a 5 day course of methylprednisolone and high dose IVIG in combination.

Entities:  

Year:  2009        PMID: 22207871      PMCID: PMC3028459          DOI: 10.1136/bcr.10.2009.2392

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.

Authors:  Karen R Sommers; Kevin M Kong; Dang T Bui; John P Fruehauf; Randall F Holcombe
Journal:  Anticancer Drugs       Date:  2003-09       Impact factor: 2.248

2.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

Authors:  Jürgen Schneck; Jean-Paul Fagot; Peggy Sekula; Bruno Sassolas; Jean Claude Roujeau; Maja Mockenhaupt
Journal:  J Am Acad Dermatol       Date:  2007-10-04       Impact factor: 11.527

3.  Association of IL4R polymorphisms with Stevens-Johnson syndrome.

Authors:  Mayumi Ueta; Chie Sotozono; Tsutomu Inatomi; Kentaro Kojima; Junji Hamuro; Shigeru Kinoshita
Journal:  J Allergy Clin Immunol       Date:  2007-09-27       Impact factor: 10.793

4.  Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.

Authors:  J Revuz; D Penso; J C Roujeau; J C Guillaume; C R Payne; J Wechsler; R Touraine
Journal:  Arch Dermatol       Date:  1987-09

5.  Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.

Authors:  O Correia; L Delgado; J P Ramos; C Resende; J A Torrinha
Journal:  Arch Dermatol       Date:  1993-04

6.  Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.

Authors:  Riichiro Abe; Tadamichi Shimizu; Akihiko Shibaki; Hideki Nakamura; Hirokazu Watanabe; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].

Authors:  Montserrat Molgó; Néstor Carreño; Rodrigo Hoyos-Bachiloglu; Max Andresen; Sergio González
Journal:  Rev Med Chil       Date:  2009-06-15       Impact factor: 0.553

8.  Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.

Authors:  Natacha Levi; Sylvie Bastuji-Garin; Maja Mockenhaupt; Jean-Claude Roujeau; Antoine Flahault; Judith P Kelly; Elvira Martin; David W Kaufman; Patrick Maison
Journal:  Pediatrics       Date:  2009-01-19       Impact factor: 7.124

9.  Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants.

Authors:  P Wolkenstein; D Charue; P Laurent; J Revuz; J C Roujeau; M Bagot
Journal:  Arch Dermatol       Date:  1995-05

10.  Management of burn injuries--recent developments in resuscitation, infection control and outcomes research.

Authors:  David J Dries
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-03-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.